Genrix (shanghai) Biopharmaceutical Co., Ltd.

This study tests a new medicine called GR1802, given as an injection alongside standard allergy treatments, for people with seasonal allergic rhinitis (hay fever). The goal is to see if it can better control symptoms like sneezing, runny nose, and itchy eyes. About 144 adults who…

This early-stage study tests a single dose of an experimental injection called GR2301 in 36 healthy adults in China. The main goal is to check if it is safe and how the body processes it. Participants will be monitored for about 16 weeks after receiving the injection or a placebo…